Search Results
187 Results Found for “immune checkpoint inhibitors, ”
Metastatic triple-negative breast cancer (mTNBC) is a clinically heterogeneous disease, but compared with other breast cancer subtypes, triple-negative breast cancer (TNBC) is generally associated with a poorer prognosis and has historically had limited therapeutic options.1 The 5-year survival rate remains ...
Choosing the appropriate adjuvant therapy in patients with melanoma undergoing neoadjuvant treatment
This article examines current evidence supporting the use of neoadjuvant immunotherapy in patients with resectable macroscopic stage III melanoma and critically discusses the selection of appropriate adjuvant therapy following surgery. It is written in the context of emerging evidence from ...
This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging ...
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide.1Â Over the past two decades, the molecular characterization of NSCLC has transformed the therapeutic landscape by enabling the development of targeted therapies that have significantly improved outcomes ...
An immunosuppressed person is one whose immune function is impaired by underlying disease and/or immunosuppressive medications, resulting in reduced immunosurveillance against malignant cells and increased vulnerability to opportunistic infections. Longstanding immunosuppression has been linked to increased risk for cutaneous (...
Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy, accounting for about 1–3% of gastrointestinal cancers.1,2 Its reported incidence has increased in recent decades, likely reflecting improved detection by balloon-assisted and capsule endoscopy and the more widespread use of cross-sectional imaging.3,4 ...
In this Future Leaders interview, Dr Kevin Keane discusses the mentors who shaped his approach to clinically meaningful research, the integration of surgery and innovation in uro-oncology and the collaborative, patient-centred advances set to transform bladder cancer care.
Pancreatic cancer (PC) is the tenth most common cancer in 2024, with 66,440 new cases and 51,570 deaths.1,2Â Globally, the prevalence varies from 10/100,000 cases in the Americas and Europe to 0.9/100,000 cases in South Central Asia and most of Africa.3Â Currently, it has the ...
The treatment paradigm for HER2-positive advanced gastric and GEJ adenocarcinoma has been reshaped by the integration of immune checkpoint inhibitors into trastuzumab-based chemotherapy. The phase III KEYNOTE-811 trial established the benefit of adding pembrolizumab to trastuzumab and chemotherapy, whereas the HERIZON-GEA-01 trial, presented at 2026 ASCO GI Cancers Symposium, explored a distinct strategy – enhancing HER2 blockade itself through substitution with the bispecific antibody zanidatamab, with or without PD-1 inhibition.
Immune checkpoint inhibitors (ICIs) act by blocking inhibitory pathways such as programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1)Â and cytotoxic T lymphocyte-associated antigen 4Â (CTLA-4), thereby restoring T-cell activity and promoting tumour cell destruction.1,2Â The ability of tumours ...
The European Society for Medical Oncology (ESMO) 2025 congress brought over 100 late-breaking abstracts, 250 sessions, 600 expert speakers and 33,800 delegates to Berlin in October. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of oncology practice.
At ESMO25, oesophageal cancer care made substantive headway: the MATTERHORN trial established a significant overall survival benefit with perioperative durvalumab plus FLOT, while SKYSCRAPER-07 offered a provocative signal of benefit for adjuvant atezolizumab after chemoradiation in squamous disease. In this interview with Dr Michael Gibson we unpack the data, the implications for multidisciplinary practice and the future research direction.
At ESMO25, Prof. Morgan Rouprêt discussed early results from the ALBAN trial, evaluating atezolizumab plus BCG in high-risk NMIBC. While event-free survival outcomes were neutral, the findings underscore the need for biomarker-driven treatment selection and personalized immunotherapy in early-stage bladder cancer.
The intestinal microbiota, composed of approximately 1,000 species and over 100 trillion micro-organisms, plays a vital role in host physiology, including metabolism, barrier function and immune regulation.1 Disruption of this delicate host–microbiota balance – known as dysbiosis – has been implicated in the ...
It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This edition showcases the continued advances and innovation reshaping cancer care, as well as highlighting the continued unmet needs and challenges associated with ...
Early-onset lung cancer is typically defined as occurring in individuals aged 18–50 years, although there is no universally accepted definition.1–3 This entity, though rare, poses unique diagnostic and therapeutic challenges. This article synthesizes current evidence on the unique features and management ...
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver, comprising approximately 85% of all primary liver cancers.1Â Globally, it ranks as the sixth-most common cancer and the third-leading cause of cancer-related mortality, with over 900,000 new cases and 830,000 deaths ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
